Rigel has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, fostamatinib, to ...
Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...